Israeli research including the Omicron phase "Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality" on AZD7442 == Evusheld - for immune-compromised - looks promising. Bring on the Evusheld! Personally I'm missing the big conference of the year in my subject partly as a result of government sluggishness on this.
See academic.oup.com/cid/advanc... and note the PDF link.